3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
5
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Neoplasms
3
Lung Neoplasms
3
Solid Tumors
1
Rectal Neoplasms
1
Pleural Effusion
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Insulin-Like Growth Factor I, Resistance To
1
Fallopian Tube Neoplasms
1
Advanced Solid Tumors
1
Adenocarcinoma
1
Interventions
vandetanib
2
Thoracoscopy
2
Povidone-Iodine
2
Cisplatin
2
dalotuzumab
1
X-Rays
1
Ultrasonography
1
Tyrosine Kinase Inhibitors
1
Tissue Plasminogen Activator
1
Tenecteplase
1
Saline Solution
1
Receptors, Vascular Endothelial Growth Factor
1
Pleurodesis
1
Pemetrexed
1
Octreotide
1
Naproxen
1
Gemcitabine
1
Fentanyl
1
Diclofenac
1
Deoxyribonucleases
1
Dasatinib
1
Darbepoetin alfa
1
Clinical Laboratory Techniques
1
Chest Tubes
1
Cdc25C phosphatase (211-221)
1
Afatinib
1
Acetaminophen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Pleural Effusion
×
dalotuzumab
×
Clear all
NCT00799240
2014-11-07
IMPACT
University of Kansas Medical Center
Phase 2
Completed
27 enrolled